Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab) for the first-line treatment of adult patients with: ...

【导读】肝细胞癌 (HCC) 仍然是全球健康的重要问题，特别是在乙型肝炎、丙型肝炎和非酒精性脂肪性肝病高发地区。免疫疗法，特别是免疫检查点抑制剂 (ICIs)，已成为晚期 HCC 的一种有前景的治疗策略。

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

In August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety and effectiveness of triplet therapy of ...

A treatment advancement could reshape the treatment landscape for hepatocellular carcinoma, the most common type of liver ...

To elucidate the molecular pathology underlying the development of hepatocellular carcinoma (HCC), we used 41 highly polymorphic microsatellite markers to examine 55 HCC and corresponding non ...

Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated advanced or unresectable hepatocellular carcinoma in ...

Fatty liver or Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting one in three adults globally, is a ...

Men with cirrhosis have a significantly higher risk for liver-related complications ― particularly hepatocellular carcinoma ― ...

Background: Hepatocellular and biliary tract carcinomas are chemoresistant and poor prognosis malignancies. After around 30 years of no drug approval, sorafenib was registered as a first line in ...